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Abstract
Background: Primary epithelial ovarian carcinoma is sub-classified into serous, mucinous, endometrioid and clear
cell subtypes. Neoadjuvant chemotherapy has become an alternative treatment option past several years, as
serous carcinoma, the most common subtype, is known as chemotherapy-sensitive tumor. On the other
hand, mucinous and clear cell carcinoma are known as chemotherapy-resistive. Therefore, it may be meaningful to
estimate subtype of ovarian carcinoma using imaging modality. The purpose of this study is to study whether CT or
MRI can determine the subtypes of epithelial ovarian cancers.
Methods: The imaging and clinical findings obtained from 125 consecutive patients with primary ovarian
carcinoma were retrospectively analyzed. Forty-four of the patients had serous carcinoma; 13, mucinous carcinoma;
53, clear cell carcinoma; and 15, endometrioid carcinoma. We studied the bilateralism, morphological type, tumor
diameter, solid portion ratio, relative signal intensity on T2WI and DWI, contrast ratio, and endometriosis on MRI and
the calcification, peritoneal dissemination and lymph node metastasis, clinical staging, and thromboembolism on CT.
We also studied the tumor markers and serum calcium concentrations. Each parameter was statistically analyzed by
univariate and multivariate analyses.
Results: Serous carcinoma showed a significantly higher incidence of bilateral disease, smaller tumor size, higher signal
intensity on DWI, and less frequent hypercalcemia. The CA19-9 level was significantly higher in mucinous carcinoma, in
which most of the tumors appeared as multilocular cystic masses. Clear cell carcinoma appeared as unilateral disease
with a larger solid portion and hypercalcemia in younger patients. Endometrioid carcinoma only showed a lower
incidence of intraperitoneal dissemination.
Conclusions: CT and MRI combined with clinical data especially tumor markers and presence of paraneoplastic
syndrome could partly predict epithelial ovarian cancer subtypes.
Keyword: Ovarian cancer, Serous carcinoma, MRI, CT, Neoadjuvant chemotherapy
Background
Primary ovarian tumors are divided into epithelial, mes-
enchymal, sex cord-stromal, or germ cell origin. Most of
malignant ovarian tumors are epithelial origin, which are
sub-classified into serous, mucinous, clear cell, and
endometrioid carcinomas [1, 2]. The biological behavior
of these subtypes and patients’ prognoses, particularly
sensitivity to chemotherapy, are quite different from one
another [3]. Serous carcinoma (SC) is the most common
subtype of epithelial ovarian carcinoma and also known
for its sensitivity to platinum-based chemotherapy. On
the other hand, the 5-year survival rate of mucinous car-
cinoma (MC) [3] and clear cell carcinoma (CCC) [4, 5] is
significantly poorer than that of serous carcinoma. The
current standard treatment for epithelial ovarian
carcinoma is primary debulking surgery (PDS) followed by
chemotherapy [6, 7]. With this treatment, clinicians can
determine the subtype of ovarian carcinoma before
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starting chemotherapy. In the past several years, how-
ever, neoadjuvant chemotherapy (NAC) followed by inter-
val debulking surgery (IDS) has become more commonly
performed as an alternative treatment option [8]. With
this type of treatment, clinicians often have to start
chemotherapy based only upon the cytological diagnosis,
in which the pathological subtype of the carcinoma is un-
clear. However, ineffective NAC may narrow the range of
therapeutic window of the patients and physicians prefer
to choose PDS for patients with chemo-resistive subtypes.
Therefore, it may be meaningful to estimate the subtype
of ovarian carcinoma using an imaging modality.
The purpose of this study was to study whether we
can determine subtypes of epithelial ovarian cancer by
using computed tomography (CT) and magnetic reson-
ance imaging (MRI) with the clinical findings, including
the tumor marker and paraneoplastic syndrome such as
venous thrombosis or hypercalcemia, to support NAC.
Methods
Patient population
This retrospective study was HIPAA-compliant and ap-
proved by the Ethics Committee of Tsukuba University
Hospital with a waiver of documentation of written
informed consent (H25-63). From January 2008 through
December 2012, 185 consecutive patients with suspected
primary ovarian cancer were treated at our institute. Seven-
teen cases with insufficient imaging or clinical information
and 43 cases with inappropriate pathological diagnosis for
this study were excluded (Fig. 1). Therefore, 125 cases (aged
31–85 years, mean age 59 years) were included in the study.
One hundred two patients were treated with PDS followed
by chemotherapy and 23, with NAC followed by IDS. The
number of patients with SC, MC, CCC, and endometrioid
carcinomas (EC) were 44, 13, 53 and 15, respectively
(Table 1).
CT and MRI examinations
Contrast CT and MRI were conducted in all cases. The
CT images were acquired at 120 kVp and between 150
and 400 mAs and were reconstructed at 2- and 5-mm
intervals with a 16 or 64 multidetector-row scanner
(Brilliance 16 or Brilliance 64; Philips Medical Systems,
Best, the Netherlands). All patients were given 800 mL
of diluted oral contrast material (sodium amidotrizoate
and meglumine amidotrizoate [Gastrografin; Bayer
Health Care, Berlin, Germany]) 1 h before the scan.
Noncontrast CT covered the entire primary lesion in the
adnexa and the contrast study covered the whole
185 consecutive patients suspected epithelial ovarian cancer treated in our institute from 2008 to 2012
17 cases without full imaging and clinical information
6 cases in which primary surgery was performed in other institute
1 case in which NAC was performed before referring to our institute 
3 cases in which imaging procedure was performed in other institute
1 case in which CT was not performed because of pregnancy
6 cases without surgical exploration
4 died during neoadjuvant chemotherapy (NAC)
2 with other reasons
43 cases with inappropriate pathological diagnosis for this study
18 may be peritoneal or fallopian tube origin
14 indistinguishable from peritoneal or fallopian tube origin
3 with primary peritoneal carcinoma
1 with primary adenocarcinoma of the fallopian tube
2 in which pathological diagnosis was impossible because of NAC
12 adenocarcinomas without subtypes
8 poorly differentiated adenocarcinoma
4 mixed adenocarcinoma
11 with non-adenocarcinoma pathology
2 small cell carcinoma
5 carcinosarcoma
4 with malignant transformation of preexisting teratoma
125 cases were included into this study
Fig. 1 Patient selection. Of the 185 consecutive patients with suspected primary ovarian cancer, 125 were included in this study. The reasons for
patient exclusion are presented
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abdomen and pelvis. Contrast-enhanced CT images were
obtained after the injection of 100 mL of a nonionic
iodinated contrast material with a concentration of
370 mg/mL (iopamidol [Iopamiron 370; Bayer Health
Care]) or 300 mg/mL (iohexol [Omnipaque 300; Daiichi-
Sankyo Health Care, Tokyo, Japan]) or 240 mg/mL
(ioversol [Optilay 240; Covidien, Dublin, Ireland]) at a
rate of 2 mL/s. Equivalent phase images were obtained
during at least one 50-s delay.
MRI was obtained with 1.5 T superconducting units
(Intera or Achieva; Philips Medical Systems). An intra-
muscular injection of hyoscine butylbromide (Buscopan;
Boehringer Ingelheim, Ingelheim, Germany) was given
to all patients to reduce bowel peristalsis. The MRI
protocol, including spin-echo T1-weighted imaging
(T1WI), fast spin-echo T2-weighted imaging (T2WI),
fat-saturated T1-weighted imaging, contrast-enhanced
and fat saturated spin-echo T1-weighted imaging with 5
mmoL of gadopentetate dimeglumine (Magnevist; Bayer
Health Care), was obtained in all cases. Additional echo-
planar diffusion-weighted images (DWI) were obtained in
98 cases. All MRIs were obtained with a slice thickness of
4 to 6 mm, an intersection gap of 0.4 to 0.6 mm, a matrix
of 320 x 320 – 512 x 512, a field of view (FOV) of 28 to
36 cm, and 2 to 4 excitations. The other MRI parameters
were as follows: (a) repetition time (TR)/echo time (TE)
53–575/11–14 msec for spin-echo T1WI; (b) TR/TE
1600–2100/100 msec, 16-echo train length for fast
spin-echo T2WI; (c) TR/TE 600–650/10–13 msec for
fat-saturated T1WI with spectral presaturation with
inversion recovery; (d) TR/TE 5000/55 msec, b-value
1000 s/mm2, 19-echo train length for DWI.
Image analysis
All the images were retrospectively reviewed by 2 trained
radiologists with more than 10 years of experience in
gynecological MRI. For cases in which the radiologists’
opinions differed, consensus extents were allocated. We
analyzed the nature of the primary lesion: its morpho-
logical type, unilateral or bilateral nature, maximum diam-
eter of the larger adnexal mass, maximum diameter of the
largest mural nodule, ratio of the solid to cystic portion,
signal intensity of the solid portion on T2WI compared
with the skeletal muscles, signal intensity of the solid part
on DWI compared with the endometrium, and intratu-
moral calcification. Morphological types were divided into
4 types by visual inspection: multilocular cystic, unilocular
cyst with a solitary mural nodule, unilocular cyst with mul-
tiple mural nodules, and multilocular cysts with a solid or
predominantly solid portion. The degree of calcification
was classified into none, a few, and multiple. The ancillary
findings were also noted: intraperitoneal dissemination,
lymph node metastasis, preoperative staging diagnosis with
CT and MRI, coexistent endometriosis, and venous throm-
bosis. On the basis of previous research [9, 10] and our
own experience, lymph node metastasis was considered
positive if either of the following was shown: solitary lymph
node larger than 10 mm in minimal diameter or clustered
lymph nodes larger than 6 mm in minimal diameter. The
endometriosis was considered positive when a multilocular
cystic adnexal mass with hemorrhagic contents and a thick
capsule or septa or adhesion in the pelvic floor was noted
[11, 12]. Venous thrombosis was considered positive if a
filling defect was present within the iliac veins or IVC on
contrast-enhanced CT.
Clinical information
Clinical information including serum levels of CA125,
CA19-9, CEA, and calcium was collected by retrospect-
ive review of the medical records. Serum calcium levels
of 10.4 mg/dl or higher were considered to indicate
hypercalcemia.
Pathological diagnosis
Pathological diagnosis was done depending on the offi-
cial pathological reports of our institute including the
subtypes of ovarian cancer, histopathological stage, and
coexisting pathology such as endometriosis.
Statistical analysis
The data were analyzed by both univariate and multi-
variate analyses. For the univariate analysis, all of the
parametric values, including age, largest tumor diameter,
largest solid portion diameter, ratio of the solid portion,
T2 signal ratio, DWI signal ratio, contrast ratio, and
levels of serum CA125, CA19-9, and CEA, were ana-
lyzed using one-way variance of analysis (ANOVA) and
the Bonferroni multiple comparison test as the post hoc
test. The nonparametric values, including bilaterality,
morphology, calcification, dissemination, lymph node
metastasis, staging, endometriosis, and thrombosis, were
analyzed using the Kruskal-Wallis test and the Dunn
multiple comparison test as the post hoc test (Prism 5
for Mac OS X; Graphpad Software, La Jolla, CA, USA).
Multivariate analysis was performed with binary logistic
regression (SPSS Statistics; IBM, New York, NY, USA).
Table 1 Patients Population
Histopathologic
Subtypes
Age (years
old)
Treatment Total Number
of CasesPDS NAC
Serous 61 (31–85) 24 20 44
Mucinous 59 (37–84) 12 1 13
Clear cell 57 (37–81) 51 2 53
Endometrioid 59 (43–84) 15 0 15
Total 59 (31–85) 102 23 125
Final objectives are shown with histopathological subtypes, age and treatment
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Results and discussion
The results for each parameter, the univariate analysis,
and the multivariate analysis are listed in Tables 2, 3,
and 4, respectively.
Serous carcinoma showed a strong prediction for bilat-
eral disease (p = .040, multivariate analysis; the same shall
apply hereinafter), smaller tumor size (p = .001), and
restricted diffusion (p = .016), especially when compared
with CCC. It also tended to appear as predominantly solid
masses, although this difference was not significant on
multivariate analysis (Fig. 2). In addition, hypercalcemia
was observed significantly less often (p = .013).
CA19-9 levels were significantly higher in MC (p = .009).
Twelve of the 13 MC appeared as multilocular cystic
Table 2 The Result of the each parameter in each subtype
Serous Mucinous Clear cell Endometrioid
Number of Patients 44 13 53 15
Age (mean) 61 59 57 59
Largest tumor diameter (mean, mm) 79.5 193.3 138.328 126.9
Largest solid part diameter (mean, mm) 50.4 24.6 63.3 57.2
Ratio of the solid part (mean) 0.70 0.14 0.48 0.47
T2 signal ratio (mean) 4.16 5.30 4.86 4.08
DWI signal ratio (mean) 1.84 1.18 1.37 1.56
Contrast Ratio (mean) 0.84 1.18 1.14 0.92
Bilaterality Unilateral 13 11 48 14
Bilateral 31 2 5 1
Morphology Multilocular cystic 1 6 0 0
Unilocular with single nodule 4 1 6 2
Unilocular with multiple nodule 1 0 16 5
Multilocular with solid 17 6 28 8
Solid 21 0 3 0
Calcification - 41 10 42 12
+ 3 3 11 3
Dissemination - 11 8 38 13
+ 3 0 1 1
++ 30 5 14 1
LNs mets - 20 9 40 11
+ 15 4 9 3
++ 9 0 4 1
Staging I 2 5 22 5
II 2 1 9 5
III 25 5 15 4
IV 15 2 7 1
Endometriosis - 36 11 32 6
+ 8 2 21 9
Thrombosis - 44 13 50 15
+ 0 0 3 0
CA125 (mean, U/ml) 2081.6 225.6 683.6 1936.5
CA19-9 (mean, U/ml) 711.9 13899.0 926.4 352.0
CEA (mean, ng/ml) 1.87 33.91 3.08 16.49
Hypercalcemia - 43 12 39 14
+ 1 1 13 1
The result of each parameter is tabulated in this table
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Table 3 The results of univariate analysis
All 4
subtypes
Serous vs
Mucinous
Serous vs
Clear cell
Serous vs
Endometrioid
Mucinous vs
Clear cell
Mucinous vs
Endometrioid
Clear cell vs
Endometrioid
P value P < 0.05 ? P < 0.05 ? P < 0.05 ? P < 0.05 ? P < 0.05 ? P < 0.05 ?
Age N.S. N.S. N.S. N.S. N.S. N.S. N.S.
Largest tumor
diameter
<0.0001 *** *** * N.S. * N.S.
Largest solid part
diameter
0.0016 N.S. N.S. N.S. *** N.S. N.S.
Ratio of the solid
part
<0.0001 *** ** N.S. ** * N.S.
T2 signal ratio N.S. N.S. N.S. N.S. N.S. N.S. N.S.
DWI signal ratio 0.0100 N.S. ** N.S. N.S. N.S. N.S.
Contrast Ratio 0.0263 N.S. N.S. N.S. N.S. N.S. N.S.
Bilaterality <0.0001 ** *** *** N.S. N.S. N.S.
Morphology <0.0001 *** *** ** N.S. N.S. N.S.
Calcification 0.2328 N.S. N.S. N.S. N.S. N.S. N.S.
Dissemination <0.0001 N.S. *** *** N.S. N.S. N.S.
LNs mets 0.0116 N.S. * N.S. N.S. N.S. N.S.
Staging <0.0001 N.S. *** ** N.S. N.S. N.S.
Endometriosis 0.0051 N.S. N.S. * N.S. N.S. N.S.
Thrombosis 0.2465 N.S. N.S. N.S. N.S. N.S. N.S.
CA125 0.0502 N.S. N.S. N.S. N.S. N.S. N.S.
CA19-9 0.0003 *** N.S. N.S. *** * N.S.
CEA <0.0001 * N.S. N.S. * N.S. N.S.
Hypercalcemia 0.0096 N.S. ** N.S. N.S. N.S. N.S.
Parametric factors were analyzed with one-way ANOVA, followed by a Bonferroni multiple comparison test was applied for a post hoc -test
Nonparametric factors were analyzed with the Kruskal-Wallis test, followed by a Dunn post hoc test
*significant with low p values, ** significant with lower p values, and ***significant with the lowest p values
Table 4 The results of multivariate analysis
B P value Odd’s ratio 95 % CI of OR
Serous adenocarcinoma Age .086 .040 1.090 1.004–1.184
Largest tumor diameter −.038 .001 .963 .942–.984
DWI signal ratio 1.544 .016 4.684 1.329–16.510
Bilaterality 2.952 .001 19.146 3.149–116.424
Hypercalcemia −3.804 .013 .022 .001–.452
Mucinous adenocarcinoma Ratio of the solid part −11.603 .039 .000 .000–.562
Calcification 1.487 .071 4.425 .882–22.195
CA19-9 .002 .009 1.002 1.000–1.003
Clear cell adenocarcinoma Age −.099 .002 .906 .850–965
Largest solid part diameter .021 .031 1.021 1.002–1.040
Bilaterality −3.000 .000 .050 .010–.258
Hypercalcemia 2.709 .011 15.009 1.859–121.174
Endometrioid adenocarcinoma Dissemination −.916 .051 .400 .160–1.003
Multivariate analysis was performed using binary logistic regression. The tables indicate only independent variables that showed multicollinearity for each subtype
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Fig. 2 A case with serous carcinoma. Small almost entirely solid small masses are replacing the bilateral ovaries (arrows, a: axial T2-weighted
image, b: axial contrast-enhanced and fat-saturated T1-weighted image). Both masses show strong restricted diffusion on diffusion-weighted
image (c, arrowheads). Note the massive ascites and thickened parietal peritoneum with a mass in the cul-de-sac (arrowhead) on sagittal and
contrast-enhanced and fat-saturated T1-weighted image (d), reflecting the extensive peritoneal dissemination
Fig. 3 A case with mucinous carcinoma. A multilocular cystic mass with varying signal intensity, so called stained-glass tumor, is seen on sagittal
T2-weighted image (arrow heads, a). After administration of contrast material, we can see some small solid parts along the septa enhanced by
contrast material (arrow heads, b: sagittal T1-weighted image, c: contrast-enhanced and fat-saturated T1-weighted image)
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masses, although this difference was not statistically
significant and only the smaller ratio of the solid por-
tion was evident (p = .039) (Fig. 3).
Clear cell carcinoma tended to appear as unilateral
disease (p = .000) with a larger solid portion (p = .031) in
younger patients (p = .002). Hypercalcemia was also
commonly seen in CCC (p = .011, Fig. 4).
Only intraperitoneal dissemination was significantly
less common in EC (p = .051). CCC and EC are subtypes
well known as complicated by endometriosis (Fig. 5)
Fig. 4 A case with clear cell carcinoma. A solitary large unilocular cystic mass with a mural nodule is demonstrated on the uterus on sagittal T2-
weighted image (a). The lack of adipose tissue between the mass and the uterus suggest adhesion, which evoke co-existing
endometriosis. In addition, the content of the cyst shows high signal intensity on sagittal fat-saturated T1-weighted image is another evidence of
hemorrhagic material included within an endometriotic cyst (b). After administration of contrast material, the mural nodule is weakly enhanced
(arrow heads, b: sagittal T1-weighted image, c: contrast-enhanced and fat-saturated T1-weighted image)
Fig. 5 A case with endometrioid carcinoma. A multilocular cystic mass with mural nodules is seen in the cul-de-sac adhering to the uterus on sa-
gittal T2-weighted image (a). The content of the cyst also shows high signal intensity on sagittal fat-saturated T1-weighted image (b), suggesting
co-existing endometriosis. The mural nodules are also well enhanced (arrow heads, c: contrast-enhanced and fat-saturated T1-weighted image).
As these imaging characteristics share those of serous and clear cell carcinoma, the specific diagnosis with imaging findings seems the most diffi-
cult among 4 subtypes
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[13, 14]; however, in this study neither subtype showed
any significant increase in endometriosis in the multi-
variate analysis.
Primary epithelial ovarian tumors are sub-classified
into serous, mucinous, clear cell, and endometrioid car-
cinomas [1, 2]. Primary debulking surgery followed by
chemotherapy is an established standard treatment for
epithelial ovarian carcinoma, having achieved excellent
therapeutic results with the use of cytotoxic agents [6, 7].
These excellent results may be due to the fact that the vast
majority of ovarian carcinoma are of the serous subtype,
particularly in the United States and Europe. On the other
hand, in the past couple of decades, the number of pri-
mary ovarian cancers accompanied by endometriosis has
rapidly increased [13, 15]. It is well known that CCC and
EC are common subtypes arising from ovarian endome-
triotic cysts [13, 15]. As the incidence of ovarian cancer
accompanied by endometriosis has become higher, the in-
cidence of CCC has become much higher in Japan than in
the United States and Europe [15]. CCC is also known as
a chemotherapy-resistant subtype of ovarian carcinoma
[4, 5]. Therefore, clinicians want to avoid NAC in patients
with this subtype.
Although the imaging findings of ovarian carcinoma
have been rarely reported, we can speculate on its mor-
phological characteristics on the basis of the macroscopic
findings reported in the pathology literature. Serous car-
cinoma has been characterized by psammomatous calcifi-
cation on CT [16], peritoneal carcinomatosis, relatively
small ovaries, and a highly elevated serum CA-125 level
[17]. Our findings revealed that bilateral disease with a
smaller tumor size is also common in SC; however, calcifi-
cation and intraperitoneal dissemination were not signifi-
cantly frequent in our results. It has also been reported
that intratumoral calcification may be observed in ovarian
carcinomas other than SC [18] and that on CT psammo-
matous calcification could not be differentiated from other
calcifications [19]. Therefore, our findings may not be sur-
prising. Recently, SC has been subdivided into low-grade
and high-grade subtypes [20]. Low-grade serous carcin-
oma (LGSC) is considered to arise from serous borderline
tumors. Serous surface papillary borderline tumors
(SSPBTs) are characterized by a papillary architecture and
internal branching pattern, like that of a sea anemone
[21]. Therefore, LGSC may resemble SSPBTs that tend to
make larger tumors. Our findings might have included a
few LGSCs, as the incidence of the LGSC has been
reported as far lower than those of high-grade serous
carcinomas [22]. We speculate that this inhomogeneity in
the SC group might have influenced the present findings.
Mucinous carcinoma is also a chemotherapy-resistant
subtype of ovarian carcinoma [3]. MRI findings character-
istic of MC have been reported as a large multilocular cys-
tic mass with varying signals [23, 24], and its so-called
stained glass-like appearance may be a hallmark of the
tumor. In this study, we classified the morphological
subtypes into 5 categories, and 12 of the 13 MC
showed multilocular cystic with and without a solid
portion. However, we could not reveal that the multi-
locular cystic mass was characteristic of MC because
many of the cases of the other subtypes also had a
multilocular cystic morphology with solid masses. The
former WHO classification of ovarian tumors classi-
fied MC into intestinal and endocervical-like subtypes
[1]. In the latest version of the WHO classification,
endocervical-like MC is defined as seromucinous carcin-
oma [2]. However, our study was performed following the
former version of the WHO classification [1] and thus
included endocervical-like MC. Endocervical-like MC
usually appears as mural nodules of endometriotic cysts
[2]. Our results also revealed a high incidence of endomet-
riosis in MC. This high incidence might suggest that
endocervical-like MC is difficult to differentiate from
CCC or EC.
Clear cell carcinoma and endometrioid carcinoma are
commonly complicated by endometriosis [13, 15].
Therefore, coexistent endometriosis may be the key find-
ing for these subtypes [14, 25, 26]. In our study, how-
ever, only CCC showed a significantly higher incidence
of endometriosis when compared with SC in the univari-
ate analysis. In addition, CCC was reported to appear as
a larger unilocular cystic mass with eccentric mural nod-
ules [27, 28], whereas in our study a large number of
CCC had multilocular cystic masses. Therefore, differen-
tiating CCC from EC based only on the imaging find-
ings seems to be difficult. On the other hand, as in
previous reports, coexistent hypercalcemia was more
commonly seen in CCC in our study [29], which may
be helpful for the differential diagnosis. Venous throm-
bosis was also reported as a frequently seen paraneo-
plastic syndrome of CCC [30]; however, our study
could only reveal that the incidence of venous throm-
bosis was lower in SC.
Endometrioid carcinoma, a chemosensitive subtype of
ovarian carcinoma, only showed a significantly lower inci-
dence of peritoneal dissemination. In other words, it did
not show any unique characteristics in its morphology.
Some limitations in our study should be pointed out.
First, we could analyze only the morphological charac-
teristics of the ovarian carcinomas, whereas numerous
histological types of tumors affect the ovaries. Therefore,
the process of differential diagnosis in daily practice may
be more complex. Second, the number of tumors that
we analyzed was limited. We included relatively larger
number of CCC as our study population included a lot
of ovarian cancer coexisting endometriosis. However, a
bigger number of tumors need to be analyzed, in particu-
lar MC and EC.
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Conclusions
In conclusion, ovarian serous carcinoma tended to appear
as smaller, bilateral masses with more highly restricted dif-
fusion without hypercalcemia.
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